ALFAXAN MULTIDOSE- alfaxalone injection, solution

País: Estados Unidos

Idioma: inglés

Fuente: NLM (National Library of Medicine)

Ingredientes activos:

ALFAXALONE (UNII: BD07M97B2A) (ALFAXALONE - UNII:BD07M97B2A)

Disponible desde:

Zoetis Inc.

Vía de administración:

INTRAVENOUS

tipo de receta:

PRESCRIPTION

indicaciones terapéuticas:

ALFAXAN MULTIDOSE is indicated for the induction and maintenance of anesthesia and for induction of anesthesia followed by maintenance with an inhalant anesthetic, in cats and dogs. ALFAXAN MULTIDOSE is contraindicated in cats and dogs with a known sensitivity to ALFAXAN MULTIDOSE or its components, or when general anesthesia and/or sedation are contraindicated. Controlled substance: ALFAXAN MULTIDOSE contains alfaxalone a neurosteroid anesthetic and a class IV controlled substance. Abuse : Alfaxalone is a central nervous system depressant that acts on GABA receptor associated chloride channels, similar to the mechanism of action of Schedule IV sedatives such as benzodiazepines (diazepam and midazolam), barbiturates (phenobarbital and methohexital) and fospropofol. In a drug discrimination behavioral test in rats, the effects of alfaxalone were recognized as similar to those of midazolam. These biochemical and behavioral data suggest that alfaxalone has an abuse potential similar to other Schedule IV se

Resumen del producto:

ALFAXAN MULTIDOSE is supplied in 10 and 20 mL multiple-dose vials containing 10 mg alfaxalone per mL.

Estado de Autorización:

New Animal Drug Application

Ficha técnica

ALFAXAN MULTIDOSE- ALFAXALONE INJECTION, SOLUTION
ZOETIS INC.
----------
ALFAXAN MULTIDOSE
For Animal Use Only
Alfaxan® Multidose CIV
(alfaxalone) 10 mg/mL
Intravenous injectable anesthetic for use in cats and dogs.
CAUTION
Federal law restricts this drug to use by or on the order of a
licensed veterinarian.
DESCRIPTION
ALFAXAN MULTIDOSE (alfaxalone) is a neuroactive steroid molecule with
properties of a
general anesthetic. Alfaxalone is chemically described as
3-α-hydroxy-5-α-pregnane-11,
20-dione, and has a molecular weight 332.5. The primary mechanism for
the anesthetic
action of alfaxalone is modulation of neuronal cell membrane chloride
ion transport,
induced by binding of alfaxalone to GABA (gamma-aminobutyric acid)
cell surface
receptors.
INDICATIONS
ALFAXAN MULTIDOSE is indicated for the induction and maintenance of
anesthesia and
for induction of anesthesia followed by maintenance with an inhalant
anesthetic, in cats
and dogs.
DOSAGE AND ADMINISTRATION
Administer by intravenous injection only. For induction, administer
ALFAXAN MULTIDOSE
over approximately 60 seconds or until clinical signs show the onset
of anesthesia,
titrating administration against the response of the patient. Rapid
administration of
ALFAXAN MULTIDOSE may be associated with an increased incidence of
cardiorespiratory depression or apnea. Apnea can occur following
induction or after the
administration of maintenance boluses of ALFAXAN MULTIDOSE. The use of
preanesthetics may reduce the ALFAXAN MULTIDOSE induction dose. The
choice and
the amount of phenothiazine, alpha -adrenoreceptor agonist,
benzodiazepine or opioid
will influence the response of the patient to an induction dose of
ALFAXAN MULTIDOSE.
WHEN USING ALFAXAN MULTIDOSE, PATIENTS SHOULD BE CONTINUOUSLY
MONITORED, AND FACILITIES FOR THE MAINTENANCE OF A PATENT AIRWAY,
ARTIFICIAL
A
2
VENTILATION, AND OXYGEN SUPPLEMENTATION MUST BE IMMEDIATELY AVAILABLE.
ALFAXAN MULTIDOSE contains preservatives. Use within 56 days of first
puncture. Any
unused ALFAXAN MULTIDOSE remaining afte